Skip to main content
峆一药业 logo

峆一药业 — Investor Relations & Filings

Ticker · 920478 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 363 across all filing types
Latest filing 2025-08-18 Board/Management Inform…
Country CN China
Listing Beijing Stock Exchange 920478

About 峆一药业

http://www.heryipharma.com/

Anhui Heyi Pharmaceutical Co., Ltd. specializes in the research, development, production, and sales of pharmaceutical intermediates and active pharmaceutical ingredients (APIs). The company focuses on providing high-quality chemical products for various therapeutic areas, including cardiovascular, central nervous system, and anti-infective treatments. With a strong emphasis on technological innovation and quality control, it operates advanced manufacturing facilities that adhere to international standards. Its product portfolio includes key intermediates for widely used medications, supporting both domestic and global pharmaceutical supply chains. The company leverages its expertise in complex chemical synthesis to offer customized solutions and reliable supply to its partners in the life sciences sector.

Recent filings

Filing Released Lang Actions
对外投资管理制度
Board/Management Information Classification · 95% confidence The document is titled as a management system for external investment by Anhui Xuyi Pharmaceutical Co., Ltd. It details internal management rules, approval authorities, supervisory mechanisms, and personnel management related to the company's external investments. The document includes resolutions from the board meeting and mentions submission to the shareholders' meeting for approval. It is a detailed internal governance document about investment management policies rather than a financial report, earnings release, or announcement of voting results. It does not contain financial statements or audit results, nor is it a transcript or presentation. It fits best under Board/Management Information (MANG) as it relates to internal management policies and board decisions on investment management.
2025-08-18 Chinese
独立董事工作制度
Governance Information Classification · 100% confidence The document is a detailed internal governance policy titled '安徽峆一药业股份有限公司独立董事工作制度' (Independent Director Work System of Anhui Xuyi Pharmaceutical Co., Ltd.). It outlines the roles, responsibilities, nomination, election, and duties of independent directors, referencing relevant laws, regulations, and stock exchange rules. It is not a financial report, earnings release, or announcement of voting results. It is a governance-related document detailing internal rules and board structure. Therefore, it fits the category of Governance Information (CGR). The document length (7537 characters) and content confirm it is the full policy text, not just an announcement or summary.
2025-08-18 Chinese
独立董事专门会议制度
Governance Information Classification · 95% confidence The document is titled as a company announcement regarding the 'Independent Directors Special Meeting System' of Anhui Xuyi Pharmaceutical Co., Ltd. It details the internal governance rules and procedures for independent directors' meetings, including voting, meeting convening, and the scope of matters to be discussed. It references company law, securities law, and stock exchange rules, indicating it is a governance-related document. There is no financial data, no audit report, no earnings information, no shareholder voting results, nor any mention of a report being published or attached. The document is a formal announcement of a governance policy or internal board procedure, which fits the category of Governance Information (CGR). The document length is 2418 characters, which is relatively short but contains substantive governance content rather than a mere announcement of a report publication or regulatory filing. Therefore, the best classification is Governance Information (CGR).
2025-08-18 Chinese
董事会审计委员会工作细则
Governance Information Classification · 95% confidence The document is titled as the "Board of Directors Audit Committee Working Rules" of Anhui Xuyi Pharmaceutical Co., Ltd. It details the structure, responsibilities, meeting procedures, and disclosure requirements of the audit committee under the board of directors. It is a governance-related document outlining internal rules and committee functions rather than a financial report, audit report, or announcement of voting results. The document is not a report publication announcement or a certification. It is a detailed governance framework document related to board committee operations and internal control oversight. Therefore, the most appropriate classification is Governance Information (CGR). The document length (4634 characters) supports it being a full governance document rather than a brief announcement.
2025-08-18 Chinese
内幕信息知情人登记管理制度
Regulatory Filings Classification · 95% confidence The document is a detailed internal management system regarding insider information registration and management for a company, including rules, responsibilities, and procedures. It is an official announcement of a board meeting resolution approving the insider information management system. There are no financial statements, earnings data, or investor presentation content. The document is not a report like an Annual Report or Interim Report, nor is it a simple announcement of a report publication. It is a regulatory compliance document related to corporate governance and insider information management. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2025-08-18 Chinese
子公司管理制度
Board/Management Information Classification · 95% confidence The document is titled as a management system for subsidiaries of Anhui Xuyi Pharmaceutical Co., Ltd., detailing internal management rules, governance, and operational procedures for subsidiaries. It includes sections on board meetings, voting results, management responsibilities, and internal controls. The document is a formal announcement of the adoption of internal management policies by the company's board of directors, dated August 19, 2025. It does not contain financial statements, audit results, or earnings data. It is not a report of financial performance or an earnings release, nor is it a regulatory filing or announcement of a report publication. The content focuses on board/management information, specifically the approval and implementation of internal management systems for subsidiaries, which fits the category of Board/Management Information (MANG). The document length (5941 characters) supports it being a substantive announcement rather than a brief notice or report publication announcement.
2025-08-18 Chinese

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.